Study of E7386 in Participants With Selected Advanced Neoplasms

• Status: Recruiting
• Trial end date: 2023-03-05
• Target enrollment: 0
• Participant gender: All

Summary

This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7386.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eisai Inc.

Criteria

Inclusion Criteria:

• Age greater than or equal to (>=) 18 years

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

• Life expectancy >=12 weeks

• Participant must have any of the following tumor types, confirmed by available histology or cytology records or current biopsy, that is advanced, nonresectable, recurrent since last antitumor therapy, in need of systemic treatment, and for which no alternative standard therapy exists:

• Dose Escalation Part: Desmoid tumors, anaplastic thyroid cancer (ATC), endometrial cancer, melanoma, colorectal carcinoma (CRC), hepatocellular carcinoma (HCC), pancreatic cancer, prostate cancer, ovarian cancer, and head and neck cancer. Enrollment of additional tumor types will be discussed with the Sponsor and agreed on a case by case basis.

• Dose Expansion Part: tumor types identified during the escalation part. Enrollment of additional tumor types will be discussed with the Sponsor and agreed on a case by case basis.

• Participants must have accessible tumors to take biopsies for performance of correlative tissue studies. Participant with inaccessible tumors for biopsy specimens may be enrolled without a biopsy upon consultation and agreement by the sponsor.

• Participants must agree to undergo skin biopsies from skin tissue that is tumor-free during the study.

• Measurable disease meeting the following criteria:

• At least 1 lesion of >=1.0 centimeter (cm) in the longest diameter for a non-lymph node or >=1.5 cm in the short-axis diameter for a lymph node that is serially measurable according to RECIST 1.1 using computerized tomography/magnetic resonance imaging (CT/MRI)

• Lesions that have had external beam radiotherapy (EBRT) or loco-regional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion.

• Adequate renal function defined as serum creatinine less than or equal to (<=) 1.5*upper limit of normal (ULN), or for participants with serum creatinine greater than (>) 1.5*ULN, the calculated creatinine clearance >=30 milliliter per minute (mL/min) (per the Cockcroft Gault formula) is acceptable

• Adequate bone marrow function:

• Absolute neutrophil count (ANC) >=1500/millimeters cubed (mm^3) (>=1.5 × 10^3/microliters [µl])

• Platelets >=100,000/mm^3 (>=100 × 10^9/Liters [L])

• Hemoglobin >=9.0 grams per deciliter (g/dL)

• Adequate liver function:

• Total bilirubin <=1.5 × ULN

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=3 × ULN (<=5 × ULN if participant has liver metastases)

• Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) <=1.5 (in the absence of therapeutic anticoagulation)

• Normal serum calcium and potassium levels as per local laboratory reference ranges

• Serum magnesium greater than or equal to lower limit of normal as per local laboratory reference ranges

• Willing and able to comply with all aspects of the protocol

• Provide written informed consent prior to any study-specific screening procedures

Exclusion Criteria:

• Other malignancy active within the previous 2 years except for basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast that has completed curative therapy

• Prior chemotherapy, immunotherapy (tumor vaccine, cytokine or growth factor given to control the cancer), or other anti-cancer therapy within less than 4 weeks before study drug administration

• Participants taking drugs, supplements, or foods that are known potent CYP3A4 inducers/inhibitors or substrates with narrow indices within less than 4 weeks before study drug administration

• Prior definitive radiation therapy within less than 6 weeks and prior palliative radiotherapy within less than 2 weeks before study drug administration. Radiopharmaceuticals (strontium, samarium) within less than 8 weeks before study drug administration.

• Participants with brain or subdural metastases are not eligible, unless the metastases are asymptomatic and do not require treatment or have been adequately treated by local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks prior to study entry. Confirmation of radiographic stability must be done by comparing the brain scan (CT or MRI) performed during the Screening Period to a brain scan performed at least 4 weeks earlier (and following local therapy where applicable) using the same imaging modality as during the Screening Period. It is not the intention of this protocol to treat participants with active brain metastasis.

• Known human immunodeficiency virus (HIV) infection

• Active infection requiring therapy, including known positive tests for Hepatitis B surface antigen and hepatitis C virus (HCV) ribonucleic acid (RNA)

• Major surgery within 4 weeks before the first dose of study drug or minor surgery within 1 week (participant must also have recovered from any surgery related toxicities to less than Common Terminology Criteria for Adverse Events [CTCAE] Grade 2)

• Immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses >10 milligrams [mg]/day prednisone or equivalent) within 2 weeks before study drug administration

• Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids except inhaled or intranasal corticosteroids (with minimal systemic absorption)

• Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (example, nausea, diarrhea, or vomiting) that might impair the bioavailability of E7386

• Prior receipt of bisphosphonate therapy for osteoporosis or symptomatic hypercalcemia or denosumab for osteoporosis

• Osteoporosis based on a T-score of <-2.5 at the left or right total hip, left or right femoral neck, or lumbar spine (L1-L4) as determined by dual energy x-ray absorptiometry (DXA) scan

• History of symptomatic vertebral fragility fracture or any fragility fracture of the hip, pelvis, wrist, or other location (defined as any fracture without a history of trauma or because of a fall from standing height or less)

• Moderate (25% or 40% decrease in the height of any vertebrae) or severe (>40% decrease in the height of any vertebra) morphometric vertebral fractures at baseline

• Vitamin D levels less than 10 nanograms per milliliter

• Bone metastases and one of the following:

• Prior history of a recent (within 1 year prior to study entry) pathologic fracture

• Lytic lesion requiring orthopedic intervention

• Bone lesion requiring an impending orthopedic intervention

• Lack of treatment with a bisphosphonate or denosumab (participants may be included if such treatment is started at least 14 days prior to Cycle 1 Day 1). Participants with previous solitary bone lesions controlled with radiotherapy are eligible.

• Participants with a fasting serum β-C-terminal telopeptide (β-CTX) concentration of >1000 picograms (pg)/mL.

• Participants with metabolic bone disease, such as hyperparathyroidism, Paget's disease, or osteomalacia

• Participants with a recent (within 6 months) history of or a newly diagnosed insufficiency fracture

• Use of other investigational drugs within 28 days or at least 5 half-lives (whichever is longer) before study drug administration. For drugs such as monoclonal antibodies with half-lives >10 days, at least 56 days is required.

• Use of any live vaccines (example, intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guérin (BCG), yellow fever, varicella, and TY21a typhoid vaccines) within 28 days prior to the first dose of study drug

• A prolonged QT/QT corrected (QTc) interval (QTc >450 milliseconds [ms]) as demonstrated by a repeated electrocardiogram (ECG). A history of risk factors for torsade de pointes (eg, heart failure, hypokalemia, family history of long QT Syndrome) or the use of concomitant medications that prolonged the QT/QTc interval.

• Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke, left ventricular ejection fraction (LVEF) <50% , cardiac arrhythmia requiring medical treatment (including oral anticoagulation) within 6 months prior to the first dose of study drug

• Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [β-hCG] test with a minimum sensitivity of 25 International Units per Liter [IU/L] or equivalent units of β-hCG). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.

• Females of childbearing potential who:

• Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (example, true abstinence if it is their preferred and usual lifestyle [defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments], an intrauterine device, a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 28 days after study drug discontinuation

• Are not currently abstinent, or do not agree to refrain from sexual activity during the study period and for 28 days after study drug discontinuation

• Are using hormonal contraceptives but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study and for 28 days after study drug discontinuation (NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal [amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause] or have been sterilized surgically [that is, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]).

• Males who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria above (that is, not of childbearing potential or practicing highly effective contraception throughout the study period and for 28 days after study drug discontinuation). No sperm donation is allowed during the study period and for 28 days after study drug discontinuation.

• Any other major illness, any history of a medical condition or a concomitant medical condition that, in the investigator's judgment, will substantially increase the risk associated with, or compromise the participant's participation in this study